Please login to the form below

Not currently logged in
Email:
Password:

Dermavant

This page shows the latest Dermavant news and features for those working in and with pharma, biotech and healthcare.

Urovant slips on phase 3 incontinence drug data

Urovant slips on phase 3 incontinence drug data

Others cued up for results include phase 3 trials of Myovant’s relugolix in uterine fibroids, endometriosis and prostate cancer, and Dermavant’s tapinarof in psoriasis.

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Dermavant strengthens executive team Dermavant strengthens executive team

    Dermavant Sciences, a biopharmaceutical company focused on delivering therapies for dermatologic conditions, has bolstered its executive team with the addition of four new hires. ... Peterson, who previously worked at Sienna Biopharmaceuticals as its

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics